Arcutis Biotherapeutics ARQT 深 沪
等待开盘 09-18 09:30:00 美东时间
17.35
+0.380
+2.24%
华盛通- 最 高17.80
- 今 开17.13
- 成交量 71.76万股
- 最 低 17.13
- 昨 收 16.97
- 总市值 20.65亿
- 52周最高 18.15
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 8.03
- 委 比 -27.27%
- 总股本 1.19亿
- 历史最高 40.88
- 量 比 0.60
- 振 幅 3.95%
- 历史最低 1.76
- 每 手 1
- 风险率 2.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
Arcutis announced new data on ZORYVE's efficacy for seborrheic dermatitis, atopic dermatitis, and psoriasis across diverse skin types and age groups, showing improved symptoms and quality of life with good tolerability.
09-17 08:00
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
ZORYVE, a FDA-approved topical medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, has won the 2025 Allure Best of Beauty Breakthrough Award. It is the first prescription topical drug for these conditions to receive this prestigious honor. ZORYVE offers unique, versatile, and safe solutions for multiple inflammatory skin diseases, providing rapid symptom relief. With cream and foam formulations, it is suitable for all s...
09-16 13:00
Arcutis Submits sNDA To Expand ZORYVE Cream Use For Plaque Psoriasis In Children As Young As 2
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and
09-03 23:47
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
Arcutis Biotherapeutics announced the submission of a supplemental New Drug Application (sNDA) to the FDA for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first and only topical PDE4 inhibitor for this age group, offering a steroid-free option for sensitive areas like the face and intertriginous regions. The submission is supported by a 4-week MUSE study and long-term safety dat...
09-03 15:43
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
08-28 19:19
Arcutis to Present at Upcoming Investor Conferences
Arcutis Biotherapeutics announced that its management will participate in three upcoming investor conferences in September 2025: Citi’s Biopharma Back to School Conference on September 3, Morgan Stanley’s Global Healthcare Conference on September 9, and HC Wainwright’s Global Investment Conference on September 10. Fire-side chats will be held at 9:45 am EDT, 2:35 pm EDT, and 10:30 am EDT, respectively. Webcasts will be available on the Company’s ...
08-19 20:00
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $22
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $20 to $22.
08-07 18:34
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report second quarter 2025 financial results and provide a business update on August 6, 2025. A conference call and webcast will be held at 4:30 p.m. ET the same day, and the webcast will be available on the Company’s website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases with a portfolio of advanced targeted topicals.
07-23 20:00
Arcutis Biotherapeutics' ZORYVE cream 0.15% received recommendation in focused guideline update for management of adult AD from AAD.
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects
06-26 20:08
